MarketResearchNest.com adds “Opium (Opioid) Addiction – Pipeline Review, H2 2017” new report to its research database. The report spread across in 114 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction – Pipeline Review, H2 2017, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.
Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=260087
The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
Alkermes Plc, Aoxing Pharmaceutical Company Inc, BioCorRx Inc, BioDelivery Sciences International Inc, Camurus AB, Fab’entech SA, Foresee Pharmaceuticals LLC, Indivior Plc, Insys Therapeutics Inc, iX Biopharma Ltd, Nemus Bioscience Inc, Novartis AG, Omeros Corp, Opiant Pharmaceuticals Inc, Orexigen Therapeutics Inc, Orexo AB, Pfizer Inc, Relmada Therapeutics Inc, Teva Pharmaceutical Industries Ltd, Titan Pharmaceuticals Inc, Zynerba Pharmaceuticals Inc
Order a Premium Purchase Report Copy at : https://www.marketresearchnest.com/purchase.php?reportid=260087
Featured News & Press Releases
Sep 01, 2017: Indivior Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal
Aug 02, 2017: Zubsolv gains preferred position on CVS Caremark 2018 Formulary
Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
Jul 31, 2017: Indivior Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder
Jul 25, 2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio
Jul 20, 2017: Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder
Jul 10, 2017: Orexigen Announces Presentation of Data for OREX-1019, Candidate for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction
Jul 06, 2017: BioCorRx to Exhibit at ASAM Conference in Dallas, Texas
Jun 29, 2017: Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology
Jun 29, 2017: Indivior Provides Update on RBP-6000
Jun 22, 2017: Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms
Jun 21, 2017: Indivior Presents Results from the Phase 3 Pivotal Study of RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder
Jun 15, 2017: Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine
Jun 13, 2017: Braeburn and Knight Therapeutics Announce Filing of PROBUPHINE in Canada
Jun 06, 2017: TSRI Anti-Heroin Vaccine Found Effective in Non-Human Primates
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=260087
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain